Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.
Previously, it has been shown that the lysosomotropic amine, chloroquine, is effective in the prevention of graft-versus-host disease (GVHD) using murine models. Because chloroquine and hydroxychloroquine suppress MHC class II antigen presentation, their mechanism of action is different to other immune suppressant drugs (cyclosporin A) currently used to control GVHD. It is possible that the use of cyclosporin A and chloroquine in combination may have an additive or synergistic effect on T cell responses to antigens presented in the context of MHC class II. We investigated the effects of chloroquine or hydroxychloroquine in combination with cyclosporin A on human T cell responses in vitro to tetanus toxoid, an exogenous protein antigen dependent on MHC class II presentation for proliferative responses. We demonstrate that similar levels of chloroquine and hydroxychloroquine suppress human T cell responses to tetanus toxoid and that the use of either agent in combination with cyclosporin A results in synergistic suppression. Evaluation for a direct effect by the lysosomotropic amines on T cells, in the absence of antigen presenting cells, revealed that there was inhibition of T cell responses but only at high concentrations. No significant decrease or increase was seen in surface MHC II or invariant chain expression or in cytoplasmic invariant chain after exposure to chloroquine. Thus, lysosomotropic amines in combination with cyclosporin A are synergistic in suppression of T cell proliferation. Use of these agents in combination with cyclosporin A may improve control of graft-versus-host disease.
Schultz
K R
KR
Department of Pediatrics, University of British Columbia, Vancouver, Canada.
Nelson
D
D
Bader
S
S
D000328:Adult; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D002738:Chloroquine / Q000494:pharmacology*; D016572:Cyclosporine / Q000494:pharmacology*; D004357:Drug Synergism; D006086:Graft vs Host Disease / Q000517:prevention & control; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D006886:Hydroxychloroquine / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology*
D000944:Antigens, Differentiation, B-Lymphocyte; D000949:Histocompatibility Antigens Class II; D007166:Immunosuppressive Agents; D013745:Tetanus Toxoid; C045084:invariant chain; D006886:Hydroxychloroquine; D016572:Cyclosporine; D002738:Chloroquine